Clinical trial

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

NCT00366340 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed

Key facts

NCT number NCT00366340
Title Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
Official title A Phase 3, Randomized, Active-Controlled, Double-blind Trial of the Safety, Tolerability, and Immunologic Non-Inferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Germany.
Lead sponsor Wyeth is now a wholly owned subsidiary of Pfizer, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Vaccines, Pneumococcal
Intervention type Biological
Interventions 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine
Enrollment 604
Start date Oct 1, 2006
Primary completion Aug 1, 2008
Completion Aug 1, 2008
First posted Aug 21, 2006
Last update posted Aug 8, 2012
Countries Germany

At a glance

  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies